Jatin J Shah

Jatin J Shah

UNVERIFIED PROFILE

Are you Jatin J Shah?   Register this Author

Register author
Jatin J Shah

Jatin J Shah

Publications by authors named "Jatin J Shah"

Are you Jatin J Shah?   Register this Author

49Publications

1599Reads

18Profile Views

A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

Am J Hematol 2019 Sep 6. Epub 2019 Sep 6.

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25633DOI Listing
September 2019

Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.

Lancet Haematol 2018 Dec;5(12):e628-e640

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23523026183017
Publisher Site
http://dx.doi.org/10.1016/S2352-3026(18)30174-1DOI Listing
December 2018

Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes.

Clin Lymphoma Myeloma Leuk 2017 09 17;17(9):575-583.e2. Epub 2017 Jun 17.

US Oncology Research, The Woodlands, TX; Medical Oncology/Hematology, Rocky Mountain Cancer Centers, Denver, CO. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2017.06.013DOI Listing
September 2017

Return to the Primary Acute Care Service Among Patients With Multiple Myeloma on an Acute Inpatient Rehabilitation Unit.

PM R 2017 Jun 8;9(6):571-578. Epub 2017 Jan 8.

Department of Palliative, Rehabilitation and Integrative Medicine, University of Texas MD Anderson Cancer Center, Houston, TX(∗∗).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pmrj.2016.12.007DOI Listing
June 2017

Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement.

Eur J Haematol 2016 Oct 15;97(4):342-7. Epub 2016 Feb 15.

Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12736DOI Listing
October 2016

Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression.

Clin Cancer Res 2016 Oct 13;22(19):4901-4912. Epub 2016 Jun 13.

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5050094PMC
http://dx.doi.org/10.1158/1078-0432.CCR-15-2242DOI Listing
October 2016

Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma.

Sci Transl Med 2016 08;8(353):353ra113

Department of Lymphoma and Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aad8949DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109917PMC
August 2016

Practical Approaches to the Management of Dual Refractory Multiple Myeloma.

Curr Hematol Malig Rep 2016 Apr;11(2):148-55

University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 429, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-016-0312-7DOI Listing
April 2016

Novel approaches to treatment of double-refractory multiple myeloma.

Am Soc Clin Oncol Educ Book 2013

From the Division of Cancer Medicine; Department of Lymphoma/Myeloma; and Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EdBook_AM.2013.33.e302DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3762449PMC
November 2015

Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics.

Clin Lymphoma Myeloma Leuk 2015 Jun 11;15(6):368-76. Epub 2014 Dec 11.

Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2014.12.002DOI Listing
June 2015

Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia.

Clin Cancer Res 2015 Jun 6;21(11):2538-45. Epub 2015 Mar 6.

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1462DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737551PMC
June 2015

Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma.

Cancer Biother Radiopharm 2013 Jun 26;28(5):370-9. Epub 2013 Mar 26.

Department of Hematology and Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

View Article

Download full-text PDF

Source
http://www.liebertpub.com/doi/10.1089/cbr.2012.1387
Publisher Site
http://dx.doi.org/10.1089/cbr.2012.1387DOI Listing
June 2013

Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.

J Biol Chem 2011 Apr 28;286(13):11009-20. Epub 2010 Dec 28.

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M110.180208DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064156PMC
April 2011

Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.

J Nucl Med 2010 Jan 15;51(1):150-7. Epub 2009 Dec 15.

Department of Radiation Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.109.066597DOI Listing
January 2010

Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity.

Cancer Biother Radiopharm 2006 Dec;21(6):553-60

Department of Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL 35294-3300, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/cbr.2006.21.553DOI Listing
December 2006

Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy.

Clin Lymphoma Myeloma 2006 Nov;7(3):236-8

Department of Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham, Comprehensive Cancer Center, AL, USA.

View Article

Download full-text PDF

Source
November 2006